<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M915</article-id>
      <article-id pub-id-type="publisher-id">molbank-2016-M915</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>(3,5-Dimethylpyrazol-1-yl)-[4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)phenyl]methanone</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bakr</surname>
            <given-names>Rania B.</given-names>
          </name>
          <xref rid="af1-molbank-2016-M915" ref-type="aff">1</xref>
          <xref rid="af2-molbank-2016-M915" ref-type="aff">2</xref>
          <xref rid="c1-molbank-2016-M915" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mehany</surname>
            <given-names>Ahmed B. M.</given-names>
          </name>
          <xref rid="af3-molbank-2016-M915" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Haider</surname>
            <given-names>Norbert</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2016-M915"><label>1</label>Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni Suef University, Beni Suef 62514, Egypt</aff>
      <aff id="af2-molbank-2016-M915"><label>2</label>Department of Pharmaceutical Chemistry, College of Pharmacy, Al Jouf University, Sakaka, Al Jouf 2014, Saudi Arabia</aff>
      <aff id="af3-molbank-2016-M915"><label>3</label>Department of Zoology, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt; <email>abelal_81@yahoo.com</email></aff>
      <author-notes>
        <corresp id="c1-molbank-2016-M915"><label>*</label>Correspondence: <email>raniabakr@ymail.com</email> or <email>rania.mohamed@pharm.bsu.edu.eg</email>; Tel.: +2-0100-4842863; Fax: +2-082-231-7958</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <volume>2016</volume>
      <issue>4</issue>
      <elocation-id>M915</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>09</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>08</day>
          <month>11</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>In an attempt to enhance cytotoxic activity of pyrazolo[3,4-<italic>d</italic>]pyrimidine core, we synthesized (3,5-dimethylpyrazol-1-yl)-[4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)phenyl]methanone (<bold>4</bold>) by reacting 4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)benzohydrazide (<bold>3</bold>) with acetylacetone. Antiproliferative activity of this compound was screened against breast (MCF-7), colon (HCT-116), and liver (HEPG-2) cancer cell lines. The tested compound exhibited cytotoxic activity with IC<sub>50</sub> = 5.00&#x2013;32.52 &#x3BC;M. Moreover, inhibitory activity of this compound was evaluated against the epidermal growth factor receptor (EGFR), the fibroblast growth factor receptor (FGFR), the insulin receptor (IR), and the vascular endothelial growth factor receptor (VEGFR). This target compound showed potent inhibitory activity, especially against FGFR with IC<sub>50</sub> = 5.18 &#x3BC;M.</p>
      </abstract>
      <kwd-group>
        <kwd>pyrazole</kwd>
        <kwd>pyrazolo[3,4-<italic>d</italic>]pyrimidine</kwd>
        <kwd>anticancer</kwd>
        <kwd>protein kinases</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-molbank-2016-M915" sec-type="intro">
      <title>1. Introduction</title>
      <p>Protein kinases play an important role in cell proliferation, differentiation, migration, metabolism, and apoptosis [<xref ref-type="bibr" rid="B1-molbank-2016-M915">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2016-M915">2</xref>]. Dysregulation of protein kinases occurs in a variety of diseases including cancer [<xref ref-type="bibr" rid="B3-molbank-2016-M915">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2016-M915">4</xref>]. Overexpression of protein kinase in tumor cells can be blocked by selective kinase inhibitors, so these inhibitors are considered a promising approach for treatment of cancer [<xref ref-type="bibr" rid="B5-molbank-2016-M915">5</xref>,<xref ref-type="bibr" rid="B6-molbank-2016-M915">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2016-M915">7</xref>,<xref ref-type="bibr" rid="B8-molbank-2016-M915">8</xref>].</p>
      <p>Pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives attract great interest because of their diverse biological and pharmacological properties. Among these properties, their anticancer effects have been extensively evaluated [<xref ref-type="bibr" rid="B9-molbank-2016-M915">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2016-M915">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2016-M915">11</xref>,<xref ref-type="bibr" rid="B12-molbank-2016-M915">12</xref>].</p>
      <p>The cytotoxic effect of this class of compounds is attributed to different mechanisms. They have been reported as acting as cyclin dependent kinase (CDK) inhibitors [<xref ref-type="bibr" rid="B13-molbank-2016-M915">13</xref>,<xref ref-type="bibr" rid="B14-molbank-2016-M915">14</xref>,<xref ref-type="bibr" rid="B15-molbank-2016-M915">15</xref>], glycogen synthase kinase (GSK) inhibitors [<xref ref-type="bibr" rid="B16-molbank-2016-M915">16</xref>,<xref ref-type="bibr" rid="B17-molbank-2016-M915">17</xref>], epidermal growth factor receptor (EGFR) inhibitors [<xref ref-type="bibr" rid="B18-molbank-2016-M915">18</xref>], and dual src/Ab1 kinase inhibitors [<xref ref-type="bibr" rid="B19-molbank-2016-M915">19</xref>].</p>
      <p>A new series of 2-(3,6-dimethyl-1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-yloxy)- <italic>N</italic>-(4-substitutedbenzylidene)acetohydrazides, specifically compound <bold>1</bold> (<xref ref-type="fig" rid="molbank-2016-M915-f001">Figure 1</xref>), displayed cytotoxic activity against breast carcinoma (MCF-7), non-small cell lung cancer (A549), and human colorectal adenocarcinoma (HT-29) cell lines, and proved to be inhibitors of EGFR protein kinase [<xref ref-type="bibr" rid="B20-molbank-2016-M915">20</xref>]. El Hamid et al. synthesized and evaluated a new set of 1-aryl-4-benzylidenehydrazinyl-3-methylsulphanyl-pyrazolo[3,4-<italic>d</italic>]pyrimidines as anti-breast cancer agents. Compound <bold>2</bold> was the most active compound in this search with an IC<sub>50</sub> equal to 7.5 nM [<xref ref-type="bibr" rid="B21-molbank-2016-M915">21</xref>]. In addition, the literature survey revealed that the pyrazole moiety represents an important pharmacophore in several anticancer active agents [<xref ref-type="bibr" rid="B22-molbank-2016-M915">22</xref>,<xref ref-type="bibr" rid="B23-molbank-2016-M915">23</xref>,<xref ref-type="bibr" rid="B24-molbank-2016-M915">24</xref>,<xref ref-type="bibr" rid="B25-molbank-2016-M915">25</xref>,<xref ref-type="bibr" rid="B26-molbank-2016-M915">26</xref>,<xref ref-type="bibr" rid="B27-molbank-2016-M915">27</xref>,<xref ref-type="bibr" rid="B28-molbank-2016-M915">28</xref>]. All these facts encouraged us to hybridize the pyrazolo[3,4-<italic>d</italic>]pyrimidine scaffold with the pyrazole nucleus in a trial to obtain a promising new anticancer active agent.</p>
    </sec>
    <sec id="sec2-molbank-2016-M915" sec-type="results">
      <title>2. Results and Discussion</title>
      <sec id="sec2dot1-molbank-2016-M915">
        <title>2.1. Chemistry</title>
        <p>(3,5-Dimethylpyrazol-1-yl)-[4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)phenyl]methanone (<bold>4</bold>) was prepared by refluxing 4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)benzohydrazide (<bold>3</bold>) [<xref ref-type="bibr" rid="B29-molbank-2016-M915">29</xref>] with acetylacetone in acetic acid for 10 h, as shown in <xref ref-type="scheme" rid="molbank-2016-M915-sch001">Scheme 1</xref>.</p>
        <p>The structure of the target compound <bold>4</bold> was elucidated by IR, <sup>1</sup>H-, and <sup>13</sup>C-NMR, MS, and elemental analysis. All data are in accordance with the assumed structure. The IR spectrum of this compound revealed the presence of a NH group at 3232 cm<sup>&#x2212;1</sup> and a C=O group at 1697 cm<sup>&#x2212;1</sup>.</p>
        <p>The <sup>1</sup>H-NMR spectrum showed two singlet signals at &#x3B4; 2.20 and 2.56 ppm corresponding to the two methyl protons in addition to a singlet signal at &#x3B4; 6.28 ppm, corresponding to the pyrazole H-4proton. Inspection of the <sup>13</sup>C-NMR spectrum indicated an appearance of two methyl peaks at &#x3B4; 13.90 and 14.27 ppm and pyrazole C4 at &#x3B4; 111.53 ppm. Finally, the mass spectrum of <bold>4</bold> demonstrated a molecular ion peak at <italic>m</italic>/<italic>z</italic> 409 (M<sup>+.</sup>) and a base peak at <italic>m</italic>/<italic>z</italic> 314.</p>
      </sec>
      <sec id="sec2dot2-molbank-2016-M915">
        <title>2.2. Pharmacological Screening</title>
        <p>The newly synthesized compound was screened in vitro for its anticancer activity against three cancer cell lines&#x2014;breast (MCF-7), liver (HEPG-2), and colon (HCT-116) cancer cell lines. The results were expressed in terms of IC<sub>50</sub> values (the concentration that resulted in a 50% inhibition of cell viability) where the well-known anticancer agents doxorubicin was used as a positive control (<xref ref-type="table" rid="molbank-2016-M915-t001">Table 1</xref>).</p>
        <p>The tested compound showed a marked antitumor activity against all the tested cell lines with IC<sub>50</sub> values of 5.00&#x2013;32.52 &#x3BC;M. Moreover, this compound was more potent (IC<sub>50</sub> = 5.00 &#x3BC;M) than doxorubicin (IC<sub>50</sub> = 5.66 &#x3BC;M) against the liver cancer cell line (HEPG-2). </p>
        <p>Furthermore, this compound was evaluated against different protein kinases such as the epidermal growth factor receptor (EGFR), the fibroblast growth factor receptor (FGFR), the insulin receptor (IR), and the vascular endothelial growth factor receptor (VEGFR) in an attempt to explore the mechanism of action of this compound. The obtained results demonstrated that this compound exhibited good inhibitory activity against all used protein kinases with IC<sub>50</sub> values of 5.18&#x2013;27.89 &#x3BC;M (<xref ref-type="table" rid="molbank-2016-M915-t002">Table 2</xref>).</p>
      </sec>
    </sec>
    <sec id="sec3-molbank-2016-M915">
      <title>3. Materials and Methods</title>
      <sec id="sec3dot1-molbank-2016-M915">
        <title>3.1. Chemistry</title>
        <p>Melting points was determined on a Thomas&#x2013;Hoover capillary apparatus and are uncorrected. Infrared (IR) spectrum was recorded as films on NaCl plates using a Nicolet 550 Series II Magna FT-IR spectrometer (Shimadzu, Kyoto, Japan). <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were measured on a BrukerAvance III 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C (Bruker AG, F&#xE4;llanden, Switzerland) with a BBFO Smart Probe and a Bruker 400 AEON Nitrogen-Free Magnet, Faculty of Pharmacy, Beni-Suef University, Egypt in DMSO-<italic>d</italic><sub>6</sub> with TMS as the internal standard, where <italic>J</italic> (coupling constant) values are estimated in Hertz (Hz), and chemical shifts were recorded in ppm &#x3B4; scale. Mass spectrum (MS) was recorded on a Hewlett Packard 5988 spectrometer (Hewlett-Packard Co., Palo Alto, CA, USA). Microanalyses for C, H, and N were carried out on a Perkin&#x2013;Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA) at the Micro analytical unit of Cairo University, Egypt All other reagents, purchased from the Aldrich Chemical Company (Milwaukee, WI, USA), were used without further purification. 4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)benzohydrazide (<bold>3</bold>) was prepared according to a literature procedure [<xref ref-type="bibr" rid="B29-molbank-2016-M915">29</xref>]. </p>
		<sec>
        <title><italic>(3,5-Dimethylpyrazol-1-yl)-[4-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl]methanone)</italic> (<bold>4</bold>)</title>
        <p>A mixture of 4-(1-phenyl-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidin-4-ylamino)benzohydrazide (<bold>3</bold>, 3.59 g, 10 mmol) and acetylacetone (1 g, 10 mmol) in acetic acid (10 mL) was heated under reflux for 10 h. After cooling, the reaction mixture was poured onto ice water. The colorless powder obtained was crystallized from ethanol to yield compound <bold>4</bold>. Mp 180&#x2013;182 &#xB0;C; yield: 56%; IR (cm<sup>&#x2212;1</sup>): 3232 (NH); 3070 (CH aromatic); 2954 (CH aliphatic); 1697 (C=O); 1608 (C=N); <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x3B4;</italic> ppm: 2.20 (s, 3H, CH<sub>3</sub>), 2.56 (s, 3H, CH<sub>3</sub>), 6.28 (s, 1H, pyrazole H-4 7.37&#x2013;7.41 (m, 1H, phenyl H-4), 7.57&#x2013;7.61 (m, 2H, phenyl H-3, H-5), 8.01 (d, <italic>J</italic> = 8.8 Hz, 2H, aminophenyl H-2, H-6), 8.09 (d, <italic>J</italic> = 8.8 Hz, 2H, aminophenyl H-3, H-5), 8.21 (s, 1H, pyrazole CH), 8.23 (s, 1H, pyrimidine CH), 8.67 (d, <italic>J</italic> = 12 Hz, 2H, phenyl H-2, H-6), 10.55 (s, 1H, NH, D<sub>2</sub>O exchangeable); <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>) <italic>&#x3B4;</italic>: 13.90, 14.27, 103.35, 111.53, 119.80, 121.45, 127.06, 127.53, 129.70, 132.74, 134.09, 138.95, 143.48, 144.85, 151.92, 153.45, 154.63, 156.34, 167.43; EIMS (<italic>m</italic>/<italic>z</italic>) 409 (M<sup>+.</sup>, 28%), 314 (100%). Anal.Calcd for C<sub>23</sub>H<sub>19</sub>N<sub>7</sub>O: C, 67.47; H, 4.68; N, 23.95. Found: C, 67.53; H, 4.42; N, 24.01.</p>
      </sec>
	  </sec>
      <sec id="sec3dot2-molbank-2016-M915">
        <title>3.2. Pharmacological Studies</title>
        <sec id="sec3dot2dot1-molbank-2016-M915">
          <title>3.2.1. Cell Viability Analysis</title>
          <p>The mammary gland breast cancer cell line (MCF-7), the human hepatocellular carcinoma cell line (HEPG-2), and the colon carcinoma cell line (HCT-116) were obtained from the American Type Culture Collection (ATCC). Doxorubicin (positive control) and all chemicals used in this study are of high analytical grade and were obtained from either Sigma-Aldrich or Biorad. The different cell lines mentioned above were used to determine the inhibitory effects of the tested compounds on cell growth using the SulphoRhodamine-B (SRB) assay using the method of Skehan et al. [<xref ref-type="bibr" rid="B30-molbank-2016-M915">30</xref>]. Cells were plated in 96 multi-well plates for 24 h before treatment with the compounds to allow attachment of the cells to the wall of the plate. Different concentrations of the tested compounds (0, 6.25, 12.5, 25, 50, and 100 &#xB5;g/mL) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compounds for 48 h at 37 &#xB0;C and in an atmosphere of 5% CO<sub>2</sub>; cells were fixed, washed, and stained with Sulforhodamine B stain. Excess stain was washed with acetic acid and attached stain was recovered with a Tris EDTA buffer. Color intensity was measured in an ELISA reader and the relation between surviving fraction and drug concentration was plotted and IC<sub>50</sub> (the concentration required for 50% inhibition of cell viability) was determined for each compound by Sigma plot software (Sigma Plot 11.0 software, Systat Software Inc.; San Jose, California).</p>
        </sec>
        <sec id="sec3dot2dot2-molbank-2016-M915">
          <title>3.2.2. Kinases Inhibitory Activity</title>
          <p>Kinase activity was determined using Kinase-Glo Plus luminescence kinase assay kit according to the previously reported method [<xref ref-type="bibr" rid="B31-molbank-2016-M915">31</xref>]. </p>
        </sec>
      </sec>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="app1-molbank-2016-M915">
        <title>Supplementary Materials</title>
        <p>The following are available online at <uri>www.mdpi.com/1422-8599/2016/4/M915</uri>, Figure S1: spectrum of compound <bold>4</bold>, Figure S2: <sup>13</sup>C-NMR spectrum of compound <bold>4</bold>, Figure S3: IR spectrum of compound <bold>4</bold>.</p>
      </app>
    </app-group>
    <ack>
      <title>Acknowledgments</title>
      <p>Rania B. Bakr is grateful to all members of the Pharmaceutical Organic Chemistry, Faculty of pharmacy, Beni-suef university for all help and supports during progress of research.</p>
    </ack>
    <notes>
      <title>Author Contributions</title>
      <p>R.B.B. conceived, designed, and performed the experiments, analyzed the data, and wrote the paper. A.B.M. performed the anticancer screening and kinase inhibitory activity. </p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2016-M915">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paul</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Mukhopadhyay</surname>
              <given-names>A.K.</given-names>
            </name>
          </person-group>
          <article-title>Tyrosine kinase-role and significance in cancer</article-title>
          <source>Int. J. Med. Sci.</source>
          <year>2004</year>
          <volume>1</volume>
          <fpage>101</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="doi">10.7150/ijms.1.101</pub-id>
          <pub-id pub-id-type="pmid">15912202</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2016-M915">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maruyama</surname>
              <given-names>I.N.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of activation of receptor tyrosine kinases: Monomers or dimers</article-title>
          <source>Cells</source>
          <year>2014</year>
          <volume>3</volume>
          <fpage>304</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="doi">10.3390/cells3020304</pub-id>
          <pub-id pub-id-type="pmid">24758840</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2016-M915">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roskoski</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>The ErbB/HER receptor protein-tyrosine kinases and cancer</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>2004</year>
          <volume>319</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbrc.2004.04.150</pub-id>
          <pub-id pub-id-type="pmid">15158434</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2016-M915">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Na</surname>
              <given-names>I.-K.</given-names>
            </name>
            <name>
              <surname>le Coutre</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer</article-title>
          <source>Biomark. Insights</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>29</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.4137/BMI.S22432</pub-id>
          <pub-id pub-id-type="pmid">26401097</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2016-M915">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sachsenmaier</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Targeting protein kinases for tumor therapy</article-title>
          <source>Oncol. Res. Treat.</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>346</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="doi">10.1159/000055106</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2016-M915">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diana</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Carbone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Barraja</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Montalbano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Parrino</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lopergolo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pennati</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zaffaroni</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cirrincione</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and Antitumor Activity of 3-(2-Phenyl-1,3-thiazol-4-yl)-1<italic>H</italic>-indoles and 3-(2-Phenyl-1,3-thiazol-4-yl)-1<italic>H</italic>-7-azaindoles</article-title>
          <source>ChemMedChem</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>1300</fpage>
          <lpage>1309</lpage>
          <pub-id pub-id-type="doi">10.1002/cmdc.201100078</pub-id>
          <pub-id pub-id-type="pmid">21523912</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2016-M915">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carbone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pennati</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Barraja</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Montalbano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Parrino</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Span&#xF2;</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Lopergolo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sbarra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Doldi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Zaffaroni</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antiproliferative activity of substituted 3[2-(1<italic>H</italic>-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[3,2-<italic>b</italic>]pyridines, marine alkaloid nortopsentin analogues</article-title>
          <source>Curr. Med. Chem.</source>
          <year>2014</year>
          <volume>21</volume>
          <fpage>1654</fpage>
          <lpage>1666</lpage>
          <pub-id pub-id-type="doi">10.2174/09298673113206660307</pub-id>
          <pub-id pub-id-type="pmid">24180279</pub-id>
        </citation>
      </ref>
      <ref id="B8-molbank-2016-M915">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carbone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Pennati</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Parrino</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lopergolo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Barraja</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Montalbano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spano&#x300;</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Sbarra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Doldi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>De Cesare</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Novel 1<italic>H</italic>-pyrrolo[2,3-<italic>b</italic>]pyridine derivative nortopsentin analogues: Synthesis and antitumor activity in peritoneal mesothelioma experimental models</article-title>
          <source>J. Med. Chem.</source>
          <year>2013</year>
          <volume>56</volume>
          <fpage>7060</fpage>
          <lpage>7072</lpage>
          <pub-id pub-id-type="doi">10.1021/jm400842x</pub-id>
          <pub-id pub-id-type="pmid">23919303</pub-id>
        </citation>
      </ref>
      <ref id="B9-molbank-2016-M915">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Ragab</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Alqasoumi</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Alafeefy</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Aboulmagd</surname>
              <given-names>S.A.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of some new pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives of expected anticancer and radioprotective activity</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>171</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2009.09.039</pub-id>
          <pub-id pub-id-type="pmid">19853327</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2016-M915">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Traxler</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bold</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Frei</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lydon</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mett</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Buchdunger</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Furet</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-<italic>d</italic>]pyrimidines</article-title>
          <source>J. Med. Chem.</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>3601</fpage>
          <lpage>3616</lpage>
          <pub-id pub-id-type="doi">10.1021/jm970124v</pub-id>
          <pub-id pub-id-type="pmid">9357527</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2016-M915">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakr</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Abdelall</surname>
              <given-names>E.K.</given-names>
            </name>
            <name>
              <surname>Abdel-Hamid</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Kandeel</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Design and synthesis of new EGFR-tyrosine kinase inhibitors containing pyrazolo[3,4-<italic>d</italic>]pyrimidine cores as anticancer agents</article-title>
          <source>Bull. Pharm. Sci. Assiut. Univ.</source>
          <year>2012</year>
          <volume>35</volume>
          <fpage>1</fpage>
          <lpage>16</lpage>
        </citation>
      </ref>
      <ref id="B12-molbank-2016-M915">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdellatif</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Abdelall</surname>
              <given-names>E.K.</given-names>
            </name>
            <name>
              <surname>Abdelgawad</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>R.R.</given-names>
            </name>
            <name>
              <surname>Bakr</surname>
              <given-names>R.B.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, docking study and antitumor evaluation of certain newly synthesized pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives</article-title>
          <source>Organ. Chem. Indian J.</source>
          <year>2014</year>
          <volume>10</volume>
          <fpage>157</fpage>
          <lpage>167</lpage>
        </citation>
      </ref>
      <ref id="B13-molbank-2016-M915">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Y.R.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>B.-S.</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>B.Y.</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>K.H.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological evaluations of pyrazolo[3,4-<italic>d</italic>]pyrimidines as cyclin-dependent kinase 2 inhibitors</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2003</year>
          <volume>38</volume>
          <fpage>525</fpage>
          <lpage>532</lpage>
          <pub-id pub-id-type="doi">10.1016/S0223-5234(03)00065-5</pub-id>
        </citation>
      </ref>
      <ref id="B14-molbank-2016-M915">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tundidor-Camba</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Caballero</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Modeling of cyclin-dependent kinase inhibition by 1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives using artificial neural network ensembles</article-title>
          <source>J. Chem. Inf. Model.</source>
          <year>2005</year>
          <volume>45</volume>
          <fpage>1884</fpage>
          <lpage>1895</lpage>
          <pub-id pub-id-type="doi">10.1021/ci050263i</pub-id>
          <pub-id pub-id-type="pmid">16309296</pub-id>
        </citation>
      </ref>
      <ref id="B15-molbank-2016-M915">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jorda</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Havl&#xED;cek</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>McNae</surname>
              <given-names>I.W.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Voller</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>S&#x30C;turc</surname>
              <given-names>A.N.</given-names>
            </name>
            <name>
              <surname>Navr&#xE1;tilov&#xE1;</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kuzma</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mistr&#xED;k</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>B&#xE1;rtek</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Pyrazolo[4,3-<italic>d</italic>]pyrimidine bioisostere of roscovitine: Evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity</article-title>
          <source>J. Med. Chem.</source>
          <year>2011</year>
          <volume>54</volume>
          <fpage>2980</fpage>
          <lpage>2993</lpage>
          <pub-id pub-id-type="doi">10.1021/jm200064p</pub-id>
          <pub-id pub-id-type="pmid">21417417</pub-id>
        </citation>
      </ref>
      <ref id="B16-molbank-2016-M915">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peat</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Boucheron</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Dickerson</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Garrido</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Peckham</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Preugschat</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Smalley</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schweiker</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.R.</given-names>
            </name>
          </person-group>
          <article-title>Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors</article-title>
          <source>Bioorgan. Med. Chem. Lett.</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>2121</fpage>
          <lpage>2125</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2004.02.036</pub-id>
          <pub-id pub-id-type="pmid">15080992</pub-id>
        </citation>
      </ref>
      <ref id="B17-molbank-2016-M915">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peat</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Garrido</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Boucheron</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Schweiker</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Dickerson</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T.Y.</given-names>
            </name>
            <name>
              <surname>Thomson</surname>
              <given-names>S.A.</given-names>
            </name>
          </person-group>
          <article-title>Novel GSK-3 inhibitors with improved cellular activity</article-title>
          <source>Bioorgan. Med. Chem. Lett.</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>2127</fpage>
          <lpage>2130</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2004.02.037</pub-id>
          <pub-id pub-id-type="pmid">15080993</pub-id>
        </citation>
      </ref>
      <ref id="B18-molbank-2016-M915">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ducray</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ballard</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Barlaam</surname>
              <given-names>B.C.</given-names>
            </name>
            <name>
              <surname>Hickinson</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Kettle</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Ogilvie</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Trigwell</surname>
              <given-names>C.B.</given-names>
            </name>
          </person-group>
          <article-title>Novel 3-alkoxy-1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors</article-title>
          <source>Bioorgan. Med. Chem. Lett.</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>959</fpage>
          <lpage>962</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.12.035</pub-id>
          <pub-id pub-id-type="pmid">18182285</pub-id>
        </citation>
      </ref>
      <ref id="B19-molbank-2016-M915">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schenone</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Brullo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bruno</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Bondavalli</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Mosti</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Maga</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Crespan</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Carraro</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Manetti</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tintori</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, biological evaluation and docking studies of 4-amino substituted 1<italic>H</italic>-pyrazolo[3,4-<italic>d</italic>]pyrimidines</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2008</year>
          <volume>43</volume>
          <fpage>2665</fpage>
          <lpage>2676</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2008.01.034</pub-id>
          <pub-id pub-id-type="pmid">18342402</pub-id>
        </citation>
      </ref>
      <ref id="B20-molbank-2016-M915">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdelgawad</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Bakr</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Alkhoja</surname>
              <given-names>O.A.</given-names>
            </name>
            <name>
              <surname>Mohamed</surname>
              <given-names>W.R.</given-names>
            </name>
          </person-group>
          <article-title>Design, synthesis and antitumor activity of novel pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives as EGFR-TK inhibitors</article-title>
          <source>Bioorgan. Chem.</source>
          <year>2016</year>
          <volume>66</volume>
          <fpage>88</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bioorg.2016.03.011</pub-id>
          <pub-id pub-id-type="pmid">27043178</pub-id>
        </citation>
      </ref>
      <ref id="B21-molbank-2016-M915">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Hamid</surname>
              <given-names>M.K.A.</given-names>
            </name>
            <name>
              <surname>Mihovilovic</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>El-Nassan</surname>
              <given-names>H.B.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of novel pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives as potential anti-breast cancer agents</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2012</year>
          <volume>57</volume>
          <fpage>323</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2012.09.031</pub-id>
          <pub-id pub-id-type="pmid">23085106</pub-id>
        </citation>
      </ref>
      <ref id="B22-molbank-2016-M915">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nitulescu</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Draghici</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Missir</surname>
              <given-names>A.V.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of new pyrazole derivatives and their anticancer evaluation</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>4914</fpage>
          <lpage>4919</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2010.07.064</pub-id>
          <pub-id pub-id-type="pmid">20728965</pub-id>
        </citation>
      </ref>
      <ref id="B23-molbank-2016-M915">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faidallah</surname>
              <given-names>H.M.</given-names>
            </name>
            <name>
              <surname>Rostom</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Al-Saadi</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological evaluation of some new substituted fused pyrazole ring systems as possible anticancer and antimicrobial agents</article-title>
          <source>Science (JKAU: Sci.)</source>
          <year>2010</year>
          <volume>22</volume>
          <fpage>177</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.4197/Sci.22-1.12</pub-id>
        </citation>
      </ref>
      <ref id="B24-molbank-2016-M915">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diana</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Carbone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Barraja</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Martorana</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gia</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>DallaVia</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cirrincione</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>3,5-Bis(3&#x2032;-indolyl)pyrazoles, analogues of marine alkaloid nortopsentin: Synthesis and antitumor properties</article-title>
          <source>Bioorgan. Med. Chem. Lett.</source>
          <year>2007</year>
          <volume>17</volume>
          <fpage>6134</fpage>
          <lpage>6137</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.09.042</pub-id>
          <pub-id pub-id-type="pmid">17911018</pub-id>
        </citation>
      </ref>
      <ref id="B25-molbank-2016-M915">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Span&#xF2;</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Parrino</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Carbone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Montalbano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Salvador</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brun</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Vedaldi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Diana</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cirrincione</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Barraja</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Pyrazolo[3,4-<italic>h</italic>]quinolines promising photosensitizing agents in the treatment of cancer</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2015</year>
          <volume>102</volume>
          <fpage>334</fpage>
          <lpage>351</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2015.08.003</pub-id>
          <pub-id pub-id-type="pmid">26295175</pub-id>
        </citation>
      </ref>
      <ref id="B26-molbank-2016-M915">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barraja</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Span&#xF2;</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Giallombardo</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Diana</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Montalbano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carbone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Parrino</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cirrincione</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of [1,2]oxazolo[5,4-<italic>e</italic>]indazoles as antitumour agents</article-title>
          <source>Tetrahedron</source>
          <year>2013</year>
          <volume>69</volume>
          <fpage>6474</fpage>
          <lpage>6477</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tet.2013.05.083</pub-id>
        </citation>
      </ref>
      <ref id="B27-molbank-2016-M915">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maggio</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Raimondi</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Raffa</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Plescia</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Cascioferro</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cancemi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tolomeo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Grimaudo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Daidone</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo [3,4-<italic>f</italic>][1,2,3,5]tetrazepin-4-(3<italic>H</italic>)-one</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2015</year>
          <volume>96</volume>
          <fpage>98</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2015.04.004</pub-id>
          <pub-id pub-id-type="pmid">25874335</pub-id>
        </citation>
      </ref>
      <ref id="B28-molbank-2016-M915">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maggio</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Raffa</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Raimondi</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Cascioferro</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Plescia</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tolomeo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Barbusca</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Cannizzo</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Mancuso</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Daidone</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and induction of G0&#x2013;G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-<italic>f</italic>][1,2,3,5]tetrazepin-4(3<italic>H</italic>)-one</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2008</year>
          <volume>43</volume>
          <fpage>2386</fpage>
          <lpage>2394</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2008.01.007</pub-id>
          <pub-id pub-id-type="pmid">18339455</pub-id>
        </citation>
      </ref>
      <ref id="B29-molbank-2016-M915">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdelall</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>BBakr</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Abdel-Hamid</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kandeel</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Enhancement to synthesize, design and dock of novel EGFR inhibitors containing pyrazolo[3,4-<italic>d</italic>]pyrimidine cores of expected anticancer activity</article-title>
          <source>OCAIJ</source>
          <year>2014</year>
          <volume>10</volume>
          <fpage>470</fpage>
          <lpage>483</lpage>
        </citation>
      </ref>
      <ref id="B30-molbank-2016-M915">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skehan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Storeng</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Scudiero</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Monks</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Vistica</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Bokesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kenney</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Boyd</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>New colorimetric cytotoxicity assay for anticancer-drug screening</article-title>
          <source>J. Natl. Cancer Inst.</source>
          <year>1990</year>
          <volume>82</volume>
          <fpage>1107</fpage>
          <lpage>1112</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/82.13.1107</pub-id>
        </citation>
      </ref>
      <ref id="B31-molbank-2016-M915">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balzano</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Santaguida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Musacchio</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>A general framework for inhibitor resistance in protein kinases</article-title>
          <source>Chem. Biol.</source>
          <year>2011</year>
          <volume>18</volume>
          <fpage>966</fpage>
          <lpage>975</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chembiol.2011.04.013</pub-id>
          <pub-id pub-id-type="pmid">21867912</pub-id>
        </citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Figure, Scheme and Tables</title>
      <fig id="molbank-2016-M915-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Chemical structures of some reported pyrazolo[3,4-<italic>d</italic>]pyrimidine derivatives as anticancer agents.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2016-M915-g001.tif"/>
      </fig>
      <fig id="molbank-2016-M915-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2016-M915-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>Synthetic pathway for target compound <bold>4</bold>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2016-M915-sch001.tif"/>
      </fig>
      <table-wrap id="molbank-2016-M915-t001" position="float">
        <object-id pub-id-type="pii">molbank-2016-M915-t001_Table 1</object-id>
        <label>Table 1</label>
        <caption>
          <p>Cytotoxic activity of compound <bold>4</bold> and doxorubicin on three cancer cell lines&#x2014;MCF-7, HEPG-2, and HCT-116.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Compound</th>
              <th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">IC<sub>50</sub> (&#x3BC;M)</th>
            </tr>
            <tr>
              <th align="center" valign="middle" style="border-bottom:solid thin">MCF-7</th>
              <th align="center" valign="middle" style="border-bottom:solid thin">HEPG-2</th>
              <th align="center" valign="middle" style=";border-bottom:solid thin">HCT-116</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle"><bold>4</bold></td>
              <td align="center" valign="middle">32.52 &#xB1; 0.02</td>
              <td align="center" valign="middle">5.00 &#xB1; 0.02</td>
              <td align="center" valign="middle">14.31 &#xB1; 0.05</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">Doxorubicin</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">2.60 &#xB1; 0.02</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">5.66 &#xB1; 0.12</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">8.48 &#xB1; 0.32</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="molbank-2016-M915-t002" position="float">
        <object-id pub-id-type="pii">molbank-2016-M915-t002_Table 2</object-id>
        <label>Table 2</label>
        <caption>
          <p>Kinase inhibitory activity of compound <bold>4</bold>.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">IC<sub>50</sub> (&#x3BC;M)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">EGFR</td>
              <td align="center" valign="middle">IR</td>
              <td align="center" valign="middle">VEGFR</td>
              <td align="center" valign="middle">FGFR</td>
            </tr>
            <tr>
              <td align="center" valign="middle" style="border-bottom:solid thin">13.47</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">10.29</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">27.89</td>
              <td align="center" valign="middle" style="border-bottom:solid thin">5.18</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </back>
</article>
